Royalty Pharma plc
RPRX
株式のランク
#863
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
株価
$62.37
時価総額
$27.77B
変化（1日）
0.20%
変化（1年）
66.42%
国
US
取引 Royalty Pharma plc (RPRX)
カテゴリー
Healthcare
Royalty Pharma plc（RPRX）の収益
Jun 2026 時点の収益 TTM: $2.54B
Royalty Pharma plc の最新の財務報告によると、現在の収益 (TTM) は $2.54B です。2024 年には $2.26B の収益があり、これは 2023 年の $2.35B と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Royalty Pharma plc の収益履歴（2015 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $2.54B | 6.64% |
| 2025 | $2.38B | 5.06% |
| 2024 | $2.26B | -3.86% |
| 2023 | $2.35B | 5.24% |
| 2022 | $2.24B | -2.28% |
| 2021 | $2.29B | 7.87% |
| 2020 | $2.12B | 16.98% |
| 2019 | $1.81B | 1.08% |
| 2018 | $1.79B | 12.33% |
| 2017 | $1.60B | -14.89% |
| 2016 | $1.88B | 13.62% |
| 2015 | $1.65B | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| $830.81M | -67.24% |
US
|
|
| - | - |
IT
|
|
| $4.88B | 92.59% |
HK
|
